摘要
对因急性白血病(AL)、恶性淋巴瘤、多发性骨髓瘤(MM)联合化疗及其他药物所致中性粒细胞缺乏症19例患者予以重组人粒细胞集落刺激因子(rhG-CSF)治疗,中性粒细胞绝对数(ANC)达显效、有效分别为13例(68.42%),2例(10.52%),总有效率78.94%;所需中位时间分别为8,14天。治疗后ANC增值1.57~11360倍,白细胞(WBC)、ANC达显效、有效时间明显缩短(P<0.005)。随着ANC增值,患者感染、使用广谱抗生素及化疗间歇时间均缩短,对患者及时进行化疗、安全渡过化疗后骨髓抑制期,进一步杀灭体内残存肿瘤细胞及缩减整体医疗费用具有重要意义。
We reported the application of recombinant human G-CSF(rhG-CSF) in 19 patients with neutropenia caused by combined chemotheropy and other drugs used for acute leukemia,lymphoma,or multiple myeloma.The absolute neutrophilic granulocyte count(ANC)increased after treatment of rhG-CSF.The therapeutical effect was divided into two groups:markedly effective and effective.13 patients showed markedly effective and 2 patients effective.The total effective rate was 78. 94%(15/20).The medium time for neutrophilic count elevation was 8 and 14 days respectively in two groups.The values of ANC increased by 1.57~11360 times.As a result of neutrophilic elevation the time of infection and use of broad-spectrum antibiotics,and interval between chemotherapy courses decreased,which were beneficial to chemotherapy and miniaturization residual diseases.
关键词
粒细胞减少
中性粒细胞
集落刺激因子
药物疗法
colony stimulating factor(CSF)
granulocyte
malignant tumor combined chemotherapy